Journey Medical Corp

NASDAQ:DERMUnited States

Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes seven branded and two authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved by the United States Food and Drug Administration (FDA) for sale, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox and Luxamend. It sells two authorized generic products, including sulconazole nitrate cream and solution and doxycycline hyclate immediate release 50mg tablets. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne.

Contact Information

Headquarters

9237 E Via De Ventura Blvd. Suite 105, Suite 105SCOTTSDALE, AZ, United States 85258

Phone

480-434-6670

Fax

302-531-3150

Executives

Executive Chairman of the Board

Lindsay Rosenwald

President, Chief Executive Officer, Director

Claude Maraoui

Interim Chief Financial Officer, Corporate Controller

Joseph Benesch

General Counsel, Corporate Secretary

Ramsey Alloush

Independent Director

Neil Herskowitz